Gallbladder Disease
Gallbladder disease — including cholelithiasis (gallstones), cholecystitis (gallbladder inflammation), and biliary disease — is a recognised class concern for agents that promote significant and rapid weight loss. The mechanisms are similar to those seen with bariatric surgery: rapid weight loss increases bile cholesterol supersaturation, promoting gallstone formation. Tirzepatide causes substantial weight loss (7–14 kg in trials), making this risk biologically plausible.
A systematic review and meta-analysis (Zeng et al., Front Endocrinol 2023, PMID 37908750; 9 trials, 9871 participants) found the composite gallbladder/biliary disease outcome was significantly higher with tirzepatide vs placebo or basal insulin (RR 1.97, 95% CI 1.14–3.42). However, this composite included all biliary events; individual components — cholelithiasis, cholecystitis, and biliary disease alone — were not significantly elevated. A separate meta-analysis (Mishra et al., J Endocr Soc 2023, PMID 36789109) found ≤1% absolute rates for acute pancreatitis, cholelithiasis, and cholecystitis across all tirzepatide doses.
The increased composite risk is consistent with the GLP-1 receptor agonist class effect (similar observations with semaglutide and liraglutide), driven primarily by rapid weight loss and its effects on bile composition. It is not specific to tirzepatide’s dual GIP/GLP-1 mechanism.
Ontology Gallbladder Disease [warns_about] Tirzepatide Gallbladder Disease [relates] Weight Loss in T2D Gallbladder Disease [relates] GLP-1 Receptor Agonism
Numbers
- Composite gallbladder/biliary disease: RR 1.97 (95% CI 1.14–3.42) vs placebo/basal insulin
- Cholelithiasis alone: Not significantly increased
- Cholecystitis alone: Not significantly increased
- Absolute event rates: ≤1% per trial (all components)
- Source: 9 trials, 9871 participants (Zeng et al., 2023)
Practical Interpretation
- Who appears most at risk: Patients with rapid or substantial weight loss; history of gallbladder disease; women; older adults
- Severity: Low absolute risk but composite risk ratio doubled — clinically worth monitoring
- Evidence type: Trial-based (systematic review of RCTs); not yet large-scale real-world pharmacovigilance
Connections
- Tirzepatide — warns_about
- Weight Loss in T2D — confounded_by (partially mediates risk)